Patents by Inventor Scott Antonia
Scott Antonia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041972Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: April 3, 2023Publication date: February 8, 2024Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari Pilon-Thomas, Scott Antonia
-
Publication number: 20230235008Abstract: Disclosed are T cell receptors (TCRs) specific for one or more neoantigens and T cells engineered to express said TCRs as well as methods of their use for treating cancer.Type: ApplicationFiled: February 16, 2021Publication date: July 27, 2023Inventors: Eric B. HAURA, Benjamin C. CREELAN, Chao WANG, Scott ANTONIA
-
A PEPTIDE-BASED SCREENING METHOD TO IDENTIFY NEOANTIGENS FOR USE WITH TUMOR INFILTRATING LYMPHOCYTES
Publication number: 20220257735Abstract: Disclosed are methods for identifying neoantigens and methods of treating cancer using neoantigens identified by said methods. The disclosure herein provide for methods for identifying neoantigens that can be used as a target for the treatment of a cancer, immunize a subject against a cancer, stimulate/induce immune responses, and/or isolate T cells that are reactive to said neoantigens.Type: ApplicationFiled: June 24, 2020Publication date: August 18, 2022Inventors: Benjamin C. CREELAN, Eric B. HAURA, Scott ANTONIA, Chao WANG -
Publication number: 20220106370Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.Type: ApplicationFiled: October 18, 2021Publication date: April 7, 2022Inventors: FREDERICK L. LOCKE, DARIO ALTIERI, SCOTT ANTONIA, CLAUDIO ANASETTI, DMITRY GABRILOVICH
-
Patent number: 11149072Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.Type: GrantFiled: August 23, 2019Date of Patent: October 19, 2021Assignees: H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: Frederick L. Locke, Dario Altieri, Scott Antonia, Claudio Anasetti, Dmitry Gabrilovich
-
Publication number: 20210253707Abstract: A method is disclosed for treating a cancer in a subject. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of a tumor vaccine. In some embodiments, the tumor vaccine comprises radiated autologous tumor cells and a cell line engineered to express GM-CSF and CD40 ligand. In some embodiments, the checkpoint inhibitor comprises an anti-PD-1 antibody (e.g., BMS 936558), anti-PD-L1 antibody (e.g., cloneM1H1), anti-CTLA-4 antibody (e.g., Ipilimumab, BMS), or any combination thereof.Type: ApplicationFiled: May 3, 2021Publication date: August 19, 2021Inventor: Scott Antonia
-
Patent number: 11071775Abstract: A method is disclosed for treating small cell lung cancer (SCLC) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (ATRA). The method can also involve administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor.Type: GrantFiled: April 4, 2016Date of Patent: July 27, 2021Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor: Scott Antonia
-
Patent number: 10995140Abstract: A method is disclosed for treating a cancer in a subject. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of a tumor vaccine. In some embodiments, the tumor vaccine comprises radiated autologous tumor cells and a cell line engineered to express GM-CSF and CD40 ligand. In some embodiments, the checkpoint inhibitor comprises an anti-PD-1 antibody (e.g., BMS 936558), anti-PD-L1 antibody (e.g., cloneM1H1), anti-CTLA-4 antibody (e.g., Ipilimumab, BMS), or any combination thereof.Type: GrantFiled: June 3, 2016Date of Patent: May 4, 2021Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventor: Scott Antonia
-
Publication number: 20200188472Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: October 21, 2019Publication date: June 18, 2020Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari Pilon-Thomas, Scott Antonia
-
Publication number: 20200017561Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.Type: ApplicationFiled: August 23, 2019Publication date: January 16, 2020Inventors: FREDERICK L. LOCKE, DARIO ALTIERI, SCOTT ANTONIA, CLAUDIO ANASETTI, DMITRY GABRILOVICH
-
Patent number: 10449227Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: GrantFiled: June 26, 2015Date of Patent: October 22, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Mark McLaughlin, David L. Morse, Shari Pilon-Thomas, Scott Antonia
-
Patent number: 10414810Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.Type: GrantFiled: May 7, 2016Date of Patent: September 17, 2019Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGYInventors: Frederick L. Locke, Dario Altieri, Scott Antonia, Claudio Anasetti, Dmitry Gabrilovich
-
Publication number: 20180162943Abstract: A method is disclosed for treating a cancer in a subject. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of a tumor vaccine. In some embodiments, the tumor vaccine comprises radiated autologous tumor cells and a cell line engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and cluster of differentiation 40 (CD40) ligand. In some embodiments, the checkpoint inhibitor comprises an anti-programmed death-1 (anti-PD-1) antibody (e.g., BMS 936558), anti-programmed death ligand-1 (anti-PD-L1) antibody (e.g., cloneMIHI), anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) antibody (e.g., Ipilimumab, BMS), or any combination thereof.Type: ApplicationFiled: June 3, 2016Publication date: June 14, 2018Inventor: Scott ANTONIA
-
Publication number: 20180118798Abstract: The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.Type: ApplicationFiled: May 7, 2016Publication date: May 3, 2018Inventors: FREDERICK L. LOCKE, DARIO ALTIERI, SCOTT ANTONIA, CLAUDIO ANASETTI, DMITRY GABRILOVICH
-
Publication number: 20180078628Abstract: A method is disclosed for treating small cell lung cancer (SCLC) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (ATRA). The method can also involve administering to the subject a therapeutically effective amount of an immune checkpoint inhibitor.Type: ApplicationFiled: April 4, 2016Publication date: March 22, 2018Inventors: Scott Antonia, Alberto Chiappori
-
Publication number: 20170202902Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: June 26, 2015Publication date: July 20, 2017Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari PILON-THOMAS, Scott ANTONIA
-
Publication number: 20150044240Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.Type: ApplicationFiled: March 11, 2014Publication date: February 12, 2015Applicant: University of South FloridaInventors: Scott Antonia, Dmitry I. Gabrilovich, Sunil Chada, Kerstin B. Menander
-
Patent number: 8668905Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.Type: GrantFiled: May 12, 2006Date of Patent: March 11, 2014Assignee: University of South FloridaInventors: Scott Antonia, Dmitry I. Gabrilovich, Sunil Chada, Kerstin B. Menander
-
Publication number: 20070003550Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.Type: ApplicationFiled: May 12, 2006Publication date: January 4, 2007Applicant: Introgen Therapeutics, Inc.Inventors: Scott Antonia, Dmitry Gabrilovich, Sunil Chada, Kerstin Menander